Lung Cancer

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.

East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Meghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.